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A TP II analogue, [l-Nal3] TP II, was synthesized by a
conventional solution method, followed by deprotec-
tion with 1M TFMSA-thioanisole (molar ratio 1:1) in
TFA  in  the  presence  of  Me 2Se  and  m-cresol  as
scavengers. The synthetic [l-Nal3] TP II, TP II and [Phe
(4 F)3] TP II were tested for comparative effect on the
impaired  T-lymphocyte  transformation  by  PHA  in
uremic patients suffering from recurrent  infectious
diseases. The synthetic analogue was found to have
stronger  restorative  activity  than  those  of  our  syn-
thetic TP II and [Phe (4 F)3] TP II.
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Introduction
Thymopoietins  are  polypeptide  hormones  of  the
thymus,  which  induce T-lymphocyte  differentiation
and  perform  a  restorative  activity  on  impaired
T-lymphocyte  transformation  by  PHA  in  uremic
patients.1–6
On the other hand, evidence of impaired immune
function  in  patients  with chronic uremia  has  been
elucidated. This impairement is reflected in depressed
cell-mediated immune function both in vitro and in
vivo and thymic atrophy with degenerative changes
has  been  observed  in  uremic  patients,  though  the
cause of thymic atrophy in uremia is as yet unknown.
In 1995, we reported that an analogue of TP II. [Phe
(4F)3] TP  II,  exhibited  stronger  restorative  activity
than that of TP II on the impaired PHA stimulation of
T-lymphocytes in vitro in uremic patients.7
In 1998, we reported that an analogue of THF-g2,
[l-Nal7]-THF-g2, which belongs to the naphtyl group
rather than the phenyl  group,  exhibited a stronger
restorative  effect  than  that  of  THF-g2  and  [Phe
(4F)7]-THF-g2  on  the  impaired  PHA  response  of
T-lymphocytes from uremic patients.8
These results seem to suggest an important role in
regulating immunological activities7,8 and prompted
us  to  synthesize  a  TP  II  analogue  containing
l-naphthylalanine  residue  instead  of  3-position  of
phenylalanine by the conventional solution method,
to examine the activity of our synthetic [l-Nal3] TP II
on the impaired T-lymphocytes of uremic patients and
to compare the relative activity between our synthetic
TP II [Phe (4F)3] TP II and [l-Nal3] TP II.
The  synthetic  route  we  employed  is  almost  the
same as those employed for our previous synthesis of
[Phe (4F)3] TP II.7
As illustrated in Fig. 1, the TFA-labile Boc group was
employed  for  N
a-protection  and  amino-acid  deriva-
tives  bearing  protective  groups  removable  by  the
thioanisole-mediated TFMSA deprotection procedure
were employed, i.e. Lys (Z), Glu (OBzl), Thr (Bzl), Asp
(OcHex) and Arg (Mts).
N
a-deprotection with TFA  was  performed  in  the
presence  of  anisole,  prior  to  each  condensation
reaction  in  the  usual  fashion.  Asp  (OcHex)  was
employed to minimize aspartimide formation during
the  synthesis  of  Asp-containing  peptides.  The
C-terminal protected dotetracontapeptide ester5 was
available  from  our  previous  synthesis  of TP  II. The
N-terminal  protected  heptapeptide,  Boc-Pro-Glu
(OBzl)-l-Nal-Leu-Glu  (OBzl)-Asp  (OcHex)-Pro-NHNH-
Troc (III), was prepared stepwise starting from Boc-
Leu-Glu (OBzl)-Asp (OcHex)-Pro-NHNH-Troc5 by the
HOBT-WSCI procedure to minimize racemization.
For  the  preparation  of  the  N-terminal  protected
hepatapeptide hydrazide containing Glu  (OBzl)  and
Asp (OcHex), Boc-Pro-Glu (OBzl)-l-Nal-Leu-Glu (OBzl)-
Asp  (O  cHex)-Pro-NHNH2 (IV),  we  employed  a
substituted hydrazide, Troc-NHNH2, which is known
to be removed by Zn in acetic acid without affecting
side chain protecting groups, such as Boc, OBzl and
OcHex, and zinc acetate was removed by treatment
with EDTA to give the required hydrazide. Boc-pro-
Glu  (OBzl)-l-Nal-Leu-Glu  (OBzl)-Asp  (OoHex)-Pro-
NHNH2 (IV), in analytically pure form. The hydrazine
test on the thin-layer chromatograms and elemental
ISSN 0962-9351 print/ISSN 1466-1861 online/00/030201-06 © 2000 Taylor & Francis Ltd 201
DOI: 10.1080/09629350020002930
Short Communication
Mediators of Inflammation, 9, 201–206 (2000)(1-7) Boc — pro — Glu (OBzl) — l — Nal — 
Leu — Glu — (OBzl) — Asp (OcHex) — Pro 
— NHNH — Troc
(8-49)  Boc — Ser (Bzl) — Val — Leu — Thr (Bzl)
 — Lys (Z) — Glu (OBzl) — Lys (Z) — Leu — 
Lys (Z) — Ser (Bzl) —Glu (OBzl) — Leu — Val
 — Ala — Asn — Asn — Val — Thr (Bzl) — Leu
 — Pro — Ala — Gly — Glu (OBzl) — Gln — 
Arg (Mts) — Lys (Z) — Asp (OcHex) — Val —
Tyr (Bzl) — Val — Glu (OBzl) — Leu — Tyr (Bzl)
 — Leu — Gln — Ser (Bzl) — Leu — Thr (Bzl)
 — Ala — Leu — Lys (Z) — Arg (Mts) — OBzl
Zn — AcOH
TFA — anisole
azide
1.  I M TFMSA — thio — anisole — m — cresolin TFA
2.  I N NH4OH
H — Pro — Glu — I — Nal — Leu — Glu — Asp — Pro —ser — Val —
Leu — Thr — Lys — Glu — Lys — Leu — Lys — Ser — Glu — Leu —
Val — Ala — Asn — Asn — Val — Tyr — Leu — Pro — Ala — Gly — Glu
 — Gln — Arg — Lys — Asp — Val — Tyr — Val — Glu — Leu — Tyr
 — Leu — Gln — Ser — Leu — Thr — Ala — Leu — Lys — Arg — OH
analysis data were consistent with homogeneity of the
desired product.
The two fragments  were assembled by  the azide
procedure, according to the route illustrated in Fig. 1.
The procedure for the coupling reaction was the use
of  mixture  of  DMF–DMSO  instead  of  DMF,  which
could dissolve both N-and C-terminal protected pep-
tides. After coupling, Gly was taken as the diagnostic
amino acid in acid hydrolysis. By comparison of the
recovery  of  Gly  with  new  incorporation  of  the
N-terminal  fragment  in  condensation,  the  reaction
was  confirmed.  The  homogeneity  of  the  purified
protected  nonatetracontapeptide  corresponding  to
the entire amino-acid sequence of [l-Nal3] TP II was
checked by  elemental analysis, TLC and amino-acid
analysis of the acid hydrolysate.
In  the  final  step  of  the  synthesis,  the  protected
nonatetracontapeptide  ester  was  treated  with  1M
TFMSA—thioanisole in TFA to remove all protective
groups. The deprotected crude peptide was purified
by  Sephadex  G-50  then  by  ion-exchange  column
chromatography on a CM-Biogel A column, followed
by preparative TLC.
The  immunological  effect  of  the  synthetic TP  II
[Phe (4F)3] TP II and [l-Nal3] TP II was examined by
the JIMRO (Japan immunoresearch Laboratories Co.
Ltd) fluorometric blast-formation test.8
Materials and methods
General experimental procedures used in this paper
are essentially the same as described in our previous
papers.6,7 Melting points are uncorrected. Rotations
were  measured  with  an Atago Polax  machine  (cell
length: 10cm). The amino-acid compositions of acid
hydrolysates were determined with a Hitachi 835–50
type amino-acid analyzer. Solvents were concentrated
in  a rotary evaporator under reduced pressure at a
temperature  of  30–45°C.  Boc  groups  of  protected
peptides were removed by TFA-anisole treatment. The
resulting amino components were chromatographed
on silica gel plates (Kieselgel G, Merck) and Rf values
refer  to  the  following  solvent  systems:  Rf9,  BuOH-
AcOH-H2O  (4:1:5);  Rf2:  BuOH-pyridine-AcOH-H2O.
The final product corresponding to the entire amino-
acid sequence of [l-Nal3] TP II was chromatographed
on cellulose plates (Merck). Rf3 value refers to BuOH-
AcOH-H2O  (4:1:1)  and  Rf4 value  refers  to  BuOH-
pyridine-AcOH-H2O  (30:20:6:24).  Troc-NHNH2 was
purchased from Kokusan Chemical Works Ltd, Japan.
Kite  for  the  fluorometric  blast-formation  test  were
purchased from Japan Immunoresearch Laboratories
Ltd, Japan. HPLC was conducted with a Shimadzu LC-
5A apparatus coupled to a m Bondapak C18 column
with a gradient of acetonitrile (15® 38%) in TFA at a
flow rate of 1.0ml/min and the eluate was monitored
at 230nm. The FAB-MS spectrum was obtained on an
Auto Spec Q (UQ Analytical Co, UK) mass spectrome-
ter equipped with an OPUS data processor.
Patient selection
Three uremic patients suffering from recurrent infec-
tious  diseases  were  selected.  Examination  of  the
cellular  immunocompetence  of  these  patients
revealed a significant decrease in blast formation by
PHA.  3H-Thymidine  incorporation  values  of  these
patients were 11,283, 10,994 and 11,342cpm respec-
tively (normal values 40,993–41,835cpm).
Venous  blood  was  obtained  from  these  uremic
patients  for  the  fluorometric  blast-formation  test.
Venous  blood  samples  from  three  healthy  donors
were used as a control. The fluorescence excitation
spectrum was measured with a UVLOG-FLOUSPEC-l
lA fluorometer.
Boc-l-Nal-Leu-Glu (OBzl)-Asp
(OcHex)-Pro-NHNH-Troc (I)
Boc-Leu-Glu  (OBzl)-Asp  (OcHex)-Pro-NHNH-Troc4
(2.4g) was treated with TFA-anisole (12–2.4ml) in an
ice-bath for 40min, then dry Et2O was added, dried
over KOH pellets in vacuo for 2h and then dissolved
in DMF (15ml) containing NMM (0.31ml). To this ice-
chilled  solution.  Boc-l-Nal-OH  (694mg),  HOBT
(372mg)  and  WSCI  (527mg)  were  successively
added. After being stirred at 4°C for 12h, the mixture
was poured into an ice-chilled 5% citric acid solution
with stirring. The precipitate thereby formed was re-
precipitated from AcOH with H2O. Yield: 2.1g (64%),
mp  141–147°C, [a]21D – 18.9° (c =  1.0,  DMF),  Rf1
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FIG. 1. Synthetic route to [l-Nal
3]-TP-II.0.59,  Rf2 0.64,  single  ninhydrin-positive  spot. Anal.
Calcd, for C54H70Cl3N7O13 ￿ 3 H2O: C, 54.71; H, 6.46;
N, 8.72. Found: C, 54.63: H, 6.50; N, 8.39.
Boc-Glu (OBzl)-l-Nal-Leu-Glu (OBzl)-Asp
(OcHex)-Pro-NHNH-Troc (II)
This compound was prepared from I (1.6g), Boc-Glu
(OBzl)-OH  (500mg),  HOBT  (237mg)  and  WSCI
(328mg) essentially in the same manner as described
for  the  preparation  of  I.  The  product  was  re-
precipitated from  hot MeOH with H2O. Yield: 1.5g
(83%), mp 129–135°C, [a]21 D - 12.3° (c = 1.0, DMF),
Rf1 0.60, Rf2 0.64, single ninhydrin-positive spot. Anal.
Calcd. for C66H83Cl3N8O16: C, 58.68; H, 6.19; N, 8.30.
Found: C, 58.49; H, 6.32; N, 8.47.
Boc-Pro-Glu (OBzl)-l-Nal-Leu-Glu (OBzl)-Asp
(OcHex)-Pro-NHNH-Troc (III)
This compound was prepared essentially in the same
manner as described for the preparation of I by using
II (1.4g), Boc-Pro-OH (250mg), HOBT (160mg) and
WSCI (232mg). The product was re-precipitated from
AcOH with H2O. Yield: 1.3g (81%), mp 127–134°C,
[a]21D - 11.5° (c = 1.0, DMF), Rf1 0.65, Rf2 0.68, single
ninhydrin-positive  spot.  Anal.  Calcd.  for
C71H90Cl3N9O17 ￿ 4 H2O: C, 56.11; H, 6.50; N, 8.29.
Found: C, 55.86; H, 6.83; N, 8.47.
Boc-Pro-Glu (OBzl)-l-Nal-Leu-Glu (OBzl)-Asp
(OcHex)-Pro-NHNH2 (IV)
The compound III (1.1g) in a mixture of AcOH (5ml)
and DMF (5ml) was treated with Zn dust (480mg) at
4°C for 2h and then at room temperature for 8h. The
solution was filtered, the filtrate was concentrated in
vacuo, and the residue was treated with 3% EDTA and
then with NaHCO3 to adjust the pH to neutral. The
resulting  powder  was  washed  with  H2O  and  re-
precipitated  from  DMF  with  H2O.  Yield:  805mg
(82%), mp 164–168°C, [a]21D - 10.1° (c = 1.0, DMF),
Rf1 0.60, Rf2 0.63, single hydrazine-positive spot. Anal.
Calcd. for C66H89N9O15: C, 64.18; H, 7.05; N, 9.91.
Found: C, 63.85; H, 7.26; N, 9.47.
Boc-Pro-Glu (OBzl)-l-Nal-Leu-Glu (OBzl)-Asp
(OcHex)-Pro-Ser (Bzl)-Val-Leu-Thr (Bzl)-Lys
(Z)-Glu (OBzl)-Lys (Z)-Leu-Lys (Z)-Ser (Bzl)-Glu
(OBzl)-Leu-Val-Ala-Asn-Asn-Val-Thr
(Bzl)-Leu-Pro-Ala-Gly-Glu (OBzl)-Gln-Arg
(Mts)-Lys (Z)-Asp (OcHex)-Val-Tyr (Bzl)-Val-Glu
(OBzl)-Leu-Tyr (Bzl)-Leu-Gln-Ser (Bzl)-Leu-Thr
(Bzl)-Ala-Leu-Lys (Z)-Arg (Mts)-OBzl (V)
Boc-(8–49)-OBzl5 (187mg)  was treated with TFA-
anisole  (3–0.6ml)  as  described  above  and
N
a-deprotected peptide was dissolved in DMF–DMSO
(1:1,  4ml)  containing  NMM  (0.003ml).  The  azide
(prepared from  112mg  of IV)  in  DMF–DMSO (1:1,
2ml)  and  NMM  (0.008ml)  were  added  and  the
mixture was stirred at –10°C for 48h. Additional azide
(prepared  from  40mg  of  IV)  in  DMF–DMSO  (1:1,
2ml) and NMM (0.003ml)  were added and stirring
was continued for an additional 18h until the solution
became  ninhydrin  negative. After  being  neutralized
with a few drops of AcOH, the mixture was poured
into ice-chilled 5% citric acid and stirred. The resulting
powder was washed successively with 5% citric acid,
H2O and MeOH. The crude product was dissolved in
DMSO containing 5% H2O (3ml) and the solution was
applied to a column of Sephadex LH-60 (3 ´ 90cm),
which was eluted with the same solvent. The fractions
with Rf1 0.54  were combined and the solvent was
removed  by  evaporation. Treatment  of  the  residue
with EtOH afforded a powder. Yield: 132mg (62%),
mp 170–177°C, [a]21D - 31.4°C (c = 1.0, DMSO), Rf1
0.54,  Rf2 0.62,  single  ninhydrin-positive  spot. Anal.
Calcd. for C435H580N64O94S2 ￿ 16 H2O: C, 61.43; H,
7.27;  N, 10.45.  Found: C, 61.10;  H, 7.53;  N. 10.40.
Amino acid ratios in a 6 N HCl hydrolysate: Leu 9.02,
Val 5.04, Ala 3.03, Gly 1.00, Pro 2.89, l-Nal 0.96, Tyr
1.93, Ser 2.88, Thr 2.95, Glu 8.02, Asp 3.99, Lys 4.98,
Arg 1.92 (recovery of Gly 86%).
H-Pro-Glu-l-Nal-Leu-Glu-Asp-Pro-Ser-Val
-Leu-Thr-Lys-Glu-Lys-Leu-Lys-Ser-Glu-
Leu-Val-Ala-Asn-Asn-Val-Thr-Leu-Pro-Ala
-Gly-Glu-Gln-Arg-Lys-Asp-Val-Tyr-Val-
Glu-Leu-Tyr-Leu-Gln-Ser-Leu-Thr-Ala-Leu
-Lys-Arg-OH (Corresponding to [l-Nal
3]-TP II) (VI)
Compound V (85mg) was treated with 1M TFMSA-
thioanisole in TFA (3ml) in the presence of m-cresol
(70ml) and Me2Se (60ml) in an ice-bath for 120min,
then the dry Et2O was added. The resulting powder
was  collected  by  centrifugation,  dried  over  KOH
pellets in vacuo for  2h and dissolved in 2% AcOH
(5ml). The solution, after being stirred with Amberlite
IRA-400 (acetate form, approximately, lg) for 30min,
was filtered. The pH of the filtrate was adjusted to pH
8.0 with l N NH4OH and after 30min to pH 6.0 with
l N AcOH and the solution was lyophilized to give a
fluffy powder. The powder was dissolved in 2% AcOH
(2ml), applied to a column of Sephadex G-50 (3.0 ´
95cm) and eluted with 2% AcOH. Individual fractions
(5ml each) were collected and absorbancy at 260nm
was  determined.  The  front  main  peak  (tube  Nos
52–58) was collected and the solvent was removed by
lyophilization. Next, the residue was dissolved in H2O
(2ml) and was applied to a column of CM-Biogel A
(2.3  ´ 12cm),  which  was  eluted  first  with  H2O
(100ml)  and then with a linear gradient from H2O
(250ml) to 0.25M NH4OAc buffer (250ml, pH 6.50).
Individual fractions (4ml  each) were  collected and
absorbancy at 260nm was determined.  The main peak
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removed by lyophilization. Analysis by TLC revealed
the presence of two ninhydrin-positive spots with Rf4
0.56 (main) and 0.79 (minor). The crude peptide was
dissolved in a small amount of H2O and subjected to
preparative TLC (cellulose  plate, 20 ´ 40cm) using
BuOH-pyridine-AcOH-H2O (30:20:6:24) as a develop-
ing solvent. The zone corresponding to Rf4 0.56 was
separated and extracted with 2% AcOH. The  single
main peak fractions were combined and the solvent
was removed by lyophilization to give a fluffy white
powder. Yield: 8.2mg (15%), [a]21D - 80.6° (c = 0.3, l
N AcOH),  Rf3 0.59,  Rf4 0.56,  single  ninhydrin-  and
Sakaguchi-positive spot. The synthetic peptide exhib-
ited a single  spot on a paper electrophoresis: Toyo
Roshi No. 51 (2 ´ 40cm), acetate buffer at pH 2.79:
mobility  8.3cm  from  the  origin  toward  the  anode
after running at 2mA, 600V for 80min. The synthetic
peptide  exhibited  a  single  peak  on  HPLC  using  a
mBondapak C18 column (0.39 ´ 30cm) at a retention
time of 14.20min, when eluted with a linear gradient
of acetonitrile (15® 38% in 20min) in 0.1% TFA at a
flow rate of 1.0ml/min (Fig. 3).
FAB-MS m/z: calculated (M + H)+ 6524, observed
(M  +  H)+ 5625.  Amino  acid  ratios  in  6N  HCl
hydrolysate: Leu 9.04, Val 5.02, Ala 2.94, Pro 2.90, Thr
2.91, Ser 2.87, l-Nal 0.93, Glu 7.96, Asp 3.88, Lys 5.03,
Arg 1.95, Tyr 2.01, Gly 1.00 (recovery of Gly 87%).
Fluorometric blast-formation test
A  3-ml  aliquot  of  venous  blood  was  drawn  into  a
syringe containing 25U/ml of heparin and then mixed
with  3ml  of  PBS.  Lymphocytes  were  isolated  in  a
Hypaque–Ficoll gradient. Lymphocytes were adjusted
to  1.0  ´ 106/ml  with  PBS. The  lymphocytes  were
cultured in 0.5ml of RPMI 1640 (Gibco) with 10% FCS
(Dainippon Pharmaceutical Co.) in microplates. Cul-
tures of each combination were incubated at 37°C in
the presence of one of our synthetic peptides in  a
humidified atmosphere of 5% CO2 in air for 12h and
then PHA (0.125%,  0.5ml) was added to each well
and incubation was continued under the same condi-
tions  for  60h.  Lymphocytes  in  each  well  were
transfered into a test tube and centrifuged for 10min
at  240´ g,  then  the  supernatant  was  added to  the
residue and stirred for 20min at room temperature;
the  lymphocytes  were  completely  destroyed  and
solubilized  by  this  procedure.  Ethidium  bromide
solution (2ml) was added to the above solution and
the  mixture  was  stirred  for  15min  at  room  tem-
perature. The fluorescence excitation spectrum was
measured essentially in the same manner as described
in our previous papers.5–8
Results and discussion
Our synthetic route to [l-Nal3] TP II is illustrated in Fig.
1, which shows two fragments selected as building
blocks to construct the entire amino-acid sequence of
[l-Nal3] TP II. Protected C-terminal dotetracontapep-
tide  ester  was  identical with that employed in  our
previous synthesis of TP II.5 Thus, one fragment, Boc-
Pro-Glu (OBzl)-l-Nal-Leu-Glu (OBzl)-Asp (OcHex)-Pro-
NHNH2 (IV),  which  covers  the  area  of  sequence
variation between TP II,5 [Phe (4F)3] TP II and [l-Nal3]
TP II, was newly synthesized.
The Boc group of Boc-(8–49)-OBzl5 was removed
by  the  usual TFA-anisole  treatment  and  the  corre-
sponding free amine was  condensed with  the pro-
tected N-terminal heptapeptide hydrazide IV by the
azide procedure to yield the protected [l-Nal3] TP II.
The protected nonatetracontapeptide ester was trea-
ted with 1M TFMSA-thioanisole in TFA in the presence
of  m-cresol and Me2Se. m-Cresol was used as addi-
tional cation scavenger to suppress a side reaction, i.e.
O-sulfation of Tyr residues. Me2Se was employed to
facilitate acidolytic cleavage of protecting groups.
The  deprotected  peptide  was  next  precipitated
with  dry  Et2O,  converted  to  the  corresponding
acetate with Amberlite  IRA-400  (acetate  form)  and
then treated with lM NH4OH to reverse a possible N
® O shift at the Ser and Thr residues.
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FIG. 2. Purification of synthetic [l-Nal
3]-TP-II by ion-exchange
chromatography on a CM-Biogel A column.
FIG. 3. HPLC profile of synthetic [l-Nal
3]-TP-II.The crude peptide was purified by gelfiltration on
Sephadex  G-50  and  then  by  ion-exchange  column
chromatography on a CM-Biogel A column with linear
gradient  elution  using  pH  6.50  ammunium  acetate
buffer (0 ® 0.25M) (Fig. 2), followed by preparative
TLC.  Desalting  on  Sephadex  G-25  gave  a  fluffy
powder,  which  exhibited  a  single  spot  (ninhydrin-
and  Sakaguchi-positive)  on  TLC  in  two  different
solvent  systems  and  on  paper  electrophoresis  (pH
2.79  acetate  buffer).  The  peptide  also  exhibited  a
single peak on HPLC (Fig. 3). The molecular weight of
the  synthetic  peptide  was  ascertained  by  FAB-MS
spectrometry. Homogeneity of the synthetic [l-Nal3]
TP II was further ascertained by amino-acid analysis
after 6N HCl hydrolysis.
In contrast with normal persons, transformation of
T-lymphocytes into lymphoblast mitotic activity after
PHA  stimuration  is  depressed  in  severe  uremic
patients with infectious diseases.
The  in  vitro effect  of  the  synthetic TP  II,5 [Phe
(4F)3] TP II and [l-Nal3] TP II on the impaired PHA
stimulation of T-lymphocytes from uremic patients is
shown in Table 1.
When peripheral T-lymphocytes isolated from ure-
mic patients were incubated with various amounts of
the synthetic TP II from 0.1 to 2.0mg/ml, restoration
of the impaired PHA stimulation of T-lymphocytes was
observed at a concentration of  1mg/ml  and above.
One of the synthetic two analogues in which Phe (3
position of TP II) was replaced by Phe (4F) exhibited
more  potent  restorative  activity  than  that  of  the
synthetic TP II (Table 2). The other synthetic peptide
[l-Nal3] TP II, exhibited the most potent restorative
activity beyond that of our synthetic TP II and [Phe
(4F)3] TP II.
The relative potency of the synthetic [l-Nal3] TP II
was four times stronger than that of the synthetic TP
II (Table 2). In  normal subjects, no effects of TP II
[Phe  (4F)3] TP II  and [l-Nal3] TP  II  were  observed
(data not shown).
In our previous paper,8 we reported that one of
our  synthetic  THF-g2  analogues,  [l-Nal7]-THF-g2,
exhibited the most potent restorative effect on the
impaired  blastogenic  response  of  PHA-stimulated
T-lymphocytes of uremic patients and similar results
were  reported  here  on  TP  II  analogues.  Between
the two analogues, [l-Nal3] TP II showed a stronger
restorative  effect  on  the  impaired  blastogenic
response  of  uremic  T-lymphocytes  than  that  of
[Phe (4F)3] TP II. This result exhibited that not only
a  4-fluorophenyl  ring  but  also  a  more  bulky  naph-
thyl  ring  could  bind  with  the  receptor  more
strongly  than  that  of TP  II. These  results  seem  to
suggest  that  aromaticity  of  the  side  chain  of  3
position  on  TP  II  is  important  for  immunological
activities.
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Table 1. Effect of synthetic TP-II, [Phe (4F)
3] – and [l-Nal
3]-TP-II on impaired PHA-stimulation of
T-lymphocytes of uremic patients
Peptide Dose (mg/ml) SI
a,b
(1) n
c n 310.6 ± 51.6
(2) n
d n 119.3 ± 54.9
f
(3) TP-II
d,e 0.1 117.5 ± 53.4
(4) TP-II
d,e 1.0 196.6 ± 52.2
g
(5) TP-II
d,e 2.0 268.3 ± 55.3
g
(6) [Phe (4F)
3]-
d,e 0.1 202.1 ± 53.6
g
(7) [Phe (4F)
3]-
d,e 1.0 270.0 ± 51.8
g
(8) [l-Nal
3]-
d,e 0.01 115.9 ± 53.2
(9) [l-Nal
3]-
d,e 0.05 198.3 ± 52.6
g
(10) [l-Nal
3]-
d,e 0.5 269.4 ± 54.6
g
(11) [l-Nal
3]-
d,e 1.0 267.9 ± 52.7
g
a Each value represents the mean ± SD of triplicate measurements.
b SI (stimulation index) was calculated according to the following formula:
SI =
I2 – Io
I1 – I0
´ 100, where I2 = mean fluorescence intensity of PHA-activated lymphocytes, I1 = fluorescence
intensity of PHA-nonactivated lymphocytes and Io = fluorescence intensity of ethidium bromide.
c Normal peripheral lymphocytes.
d Patient’s lymphocytes.
e Incubation was carried out at 37°C in a humidified atmosphere of 5% CO2 in air for 12h.
f The significance  of differences  of  mean values  was analyzed by  means  of  Student’s  t-test,  p <  0.03 as
compared with1.
g The significance  of differences  of  mean values  was analyzed by  means  of  Student’s  t-test,  p <  0.01 as
compared with ref.2
Table 2. Relative potencies of synthetic TP II, [Phe (4F)
3] TP II
and [l-Nal
3] TP II
Peptide Relative potency
(molar basis)
TP II 1.00
[Phe (4F)
3] TP II 2.98
[l-Nal
3] TP II 4.03Abbreviations
TP, thymopoietin; l-Nal, l-naphythylalanine; Phe (4F),
4-fluoro-acetic acid; Z, benzyloxycarbonyl; OBzl, ben-
zyl ester; Boc, tert-butoxycarbonyl; Troc, b, b, b-tri-
chloroethoxycarbonyl; Bzl,  benzyl;  Mts,  mesitylene-
2-sulfonyl;  OcHex,  cyclohexyl  ester;  HOBT,
l-hy-droxybenzotriazole; WSCI,  l-ethyl-3-(3-dimethyla-
minopropyl)  carbodimide;  NMM,  N-methyl-
morpholine; EDTA, ethylenedi-aminetetraacetic acid;
DMF,  dimethyformamide;  SMSO,  dimethylsufoxide;
TFMSA, trifluoromethanesulfonic acid; PHA, phytohe-
magglutinin; SDS, sodium dodecyl sulfate; PBS, phos-
phate-buffered saline; RPMI, Rosewell Park Memorial
Institute;  FCS,  fetal  calf  serum; AcOH,  acetic  acid;
Et2O,  ethyl  ether; TLC,  thin-layer  chromatography;
HPLC, high performance liquid chromatography; THF,
thymic humoral factor.
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